# A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R

> **NCT05470829** · PHASE1 · COMPLETED · sponsor: **Shanghai Zhimeng Biopharma, Inc.** · enrollment: 42 (actual)

## Conditions studied

- Healthy Volunteers
- Hepatitis B, Chronic

## Interventions

- **DRUG:** ZM-H1505R
- **OTHER:** ZM-H1505R Placebo

## Key facts

- **NCT ID:** NCT05470829
- **Lead sponsor:** Shanghai Zhimeng Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-27
- **Primary completion:** 2021-11-17
- **Final completion:** 2021-11-17
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05470829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05470829, "A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05470829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*